Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Stomach Neoplasms 13Carcinoma, Non-Small-Cell Lung 13Carcinoma, Hepatocellular 6Adenocarcinoma 6Neoplasms 5Lung Neoplasms 4Colorectal Neoplasms 4Colonic Neoplasms 4Breast Neoplasms 4Urethral Neoplasms 3Rectal Neoplasms 3Neoplasm Metastasis 3Liver Neoplasms 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Ureteral Neoplasms 2Solid Tumors 2Sarcoma 2Non-small Cell Lung Cancer Metastatic 2Malignant Solid Tumor 2Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Biliary Tract Neoplasms 2Thymoma 1Solid Tumor 1Sarcoma, Synovial 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

tusamitamab ravtansine 2Ramucirumab 2Gemcitabine 2Docetaxel 2pembrolizumab 1necitumumab 1Paclitaxel 1LY3023414 1Erlotinib Hydrochloride 1Cisplatin 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Non-small Cell Lung Cancer Metastatic × Ramucirumab × Clear all
NCT04394624 2025-06-06

CARMEN-LC04

Sanofi

Phase 2 Terminated
31 enrolled 22 charts
Thoracic

Non-small Cell Lung Cancer Metastatic

NCT01703091 2019-09-30

A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer

Eli Lilly and Company

Phase 2 Completed
197 enrolled 12 charts
Thoracic

Non-small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡